A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Authors

Christopher L. Bowlus, University of California at Davis
Michael R. Galambos, Piedmont Atlanta Hospital
Richard J. Aspinall, Portsmouth Hospitals University NHS Trust
Gideon M. Hirschfield, University Health Network University of Toronto
David E.J. Jones, Newcastle University
Yvonne Dörffel, Charité Universitätsmedizin Berlin
Stuart C. Gordon, Henry Ford Health System
Stephen A. Harrison, Pinnacle Clinical Research
Andreas E. Kremer, Friedrich-Alexander University Erlangen-Nürnberg
Marlyn J. Mayo, University of Texas Southwestern Medical Center
Paul J. Thuluvath, Mercy Medical Center Baltimore
Cynthia Levy, University of Miami
Mark G. Swain, University of Calgary
Guy W. Neff, LLC
David A. Sheridan, Peninsula Medical School
Carmen M. Stanca, New York University
Christoph P. Berg, University of Tübingen
Aparna Goel, Stanford University
Mitchell L. Shiffman, Liver Institute of Virginia
John M. Vierling, Baylor College of Medicine
Pol Boudes, Inc.
Alexandra Steinberg, Inc.
Yun Jung Choi, Inc.
Charles A. McWherter, Inc.

ORCID

• David A. Sheridan: 0000-0001-5100-814X

DOI

10.1016/j.jhep.2022.02.033

Publication Date

2022-03-30

Publication Title

Journal of Hepatology

ISSN

0168-8278

Embargo Period

2022-04-23

Recommended Citation

Bowlus, C., Galambos, M., Aspinall, R., Hirschfield, G., Jones, D., Dörffel, Y., Gordon, S., Harrison, S., Kremer, A., Mayo, M., Thuluvath, P., Levy, C., Swain, M., Neff, G., Sheridan, D., Stanca, C., Berg, C., Goel, A., Shiffman, M., Vierling, J., Boudes, P., Steinberg, A., Choi, Y., & McWherter, C. (2022) 'A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis', Journal of Hepatology, . Available at: 10.1016/j.jhep.2022.02.033